abrdn Life Sciences Investors
HQL
70 hedge funds and large institutions have $81.3M invested in abrdn Life Sciences Investors in 2020 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 25 increasing their positions, 21 reducing their positions, and 11 closing their positions.
25% more capital invested
Capital invested by funds: $65.2M → $81.3M (+$16.1M)
19% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 21
1% more funds holding
Funds holding: 69 → 70 (+1)
9% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 11
0.16% more ownership
Funds ownership: 19.12% → 19.28% (+0.16%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
1832 Asset Management
Toronto,
Ontario, Canada
|
+$2.56M |
| 2 |
Lazard Asset Management
New York
|
+$2.55M |
| 3 |
MC
Matisse Capital
Portland,
Oregon
|
+$2.2M |
| 4 |
1CP
1607 Capital Partners
Richmond,
Virginia
|
+$1.74M |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$1.03M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
-$5.19M |
| 2 |
KIM
Karpus Investment Management
Pittsford,
New York
|
-$1.24M |
| 3 |
CRC
Curi RMB Capital
Chicago,
Illinois
|
-$770K |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$681K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$506K |
HQL Hedge Fund Activity: Q2 2020 in Review
70 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in abrdn Life Sciences Investors (HQL) for Q2 2020, worth a combined $81.3M — up 25% from $65.2M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new HQL positions and 11 closed out — a net gain of 1 holder — while 25 added to existing stakes and 21 trimmed.
The largest buyer was 1832 Asset Management, adding an estimated $2.56M. The largest seller was Wolverine Asset Management, cutting an estimated $5.19M.
- 70 institutional investors held abrdn Life Sciences Investors (HQL) as of Q2 2020, up from 69 in Q1 2020.
- Funds reported $81.3M of abrdn Life Sciences Investors stock for Q2 2020, up 25% quarter-over-quarter.
- 12 funds opened new abrdn Life Sciences Investors positions in Q2 2020 and 11 closed out, a net change of +1 holder.
- The largest abrdn Life Sciences Investors buyer in Q2 2020 was 1832 Asset Management, an estimated $2.56M added.
- The largest abrdn Life Sciences Investors seller in Q2 2020 was Wolverine Asset Management, an estimated $5.19M sold.
Based on aggregated 13F filings for Q2 2020.